Schroder Investment Management Group’s Denali Therapeutics DNLI Stock Holding History

Schroder Investment Management Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-285,820	Closed	-$5.17M	–	1191
2026 Q1	$5.17M	Sell	285,820 -165,165	-37%	-$3.29M	﹤0.01%	778
2025 Q4	$7.4M	Buy	450,985 +241,390	+115%	+$4.07M	0.01%	689
2025 Q3	$3.04M	Sell	209,595 -176,944	-46%	-$2.54M	﹤0.01%	855
2025 Q2	$5.41M	Buy	386,539 +94,744	+32%	+$1.33M	﹤0.01%	754
2025 Q1	$4.31M	Buy	291,795 +43,995	+18%	+$843K	﹤0.01%	782
2024 Q4	$5.02M	Buy	247,800 +120,494	+95%	+$3.08M	﹤0.01%	768
2024 Q3	$3.75M	Sell	127,306 -218,067	-63%	-$5.41M	﹤0.01%	844
2024 Q2	$8.02M	Buy	+345,373	New	+$6.63M	0.01%	677
2024 Q1	–	Sell	-154,000	Closed	-$3.3M	–	1207
2023 Q4	$3.3M	Buy	+154,000	New	+$3.05M	﹤0.01%	837

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group's DNLI Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 285,820 shares — an estimated $5.17M sold.

Schroder Investment Management Group first reported a position in DNLI in Q4 2023 and held it in 9 quarters. The position peaked at $8.02M in Q2 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Schroder Investment Management Group reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Schroder Investment Management Group sold 285,820 Denali Therapeutics shares in Q2 2026, an estimated $5.17M.
Schroder Investment Management Group first reported a position in Denali Therapeutics in Q4 2023 and held it in 9 quarters.
Schroder Investment Management Group's Denali Therapeutics position peaked at $8.02M in Q2 2024.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.